220438-80-2

Basic information

• Product Name: (4-Carboxy-3-ethoxy)phenyl Acetic Acid (Repaglinide Impurity)
• Synonyms: 4-(carboxyMethyl)-3-ethoxybenzoic acid;Repaglinide EP IMpurity A;4-(CarboxyMethyl)-2-ethoxybenzoic acid;(4-Carboxy-3-ethoxy)phenyl Acetic Acid
• CAS NO: 220438-80-2
• Molecular Formula: C₁₁H₁₂O₅
• Molecular Weight: 224.20998
• Product Categories: Impurities;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 220438-80-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 140-142?C
• Boiling Point: 428.1±35.0 °C(Predicted)
• Appearance: /
• Density: 1.319±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 3.96±0.10(Predicted)
• CAS DataBase Reference: (4-Carboxy-3-ethoxy)phenyl Acetic Acid (Repaglinide Impurity)(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Carboxy-3-ethoxy)phenyl Acetic Acid (Repaglinide Impurity)(220438-80-2)
• EPA Substance Registry System: (4-Carboxy-3-ethoxy)phenyl Acetic Acid (Repaglinide Impurity)(220438-80-2)

Safety Data

• Hazardous Substances Data: 220438-80-2(Hazardous Substances Data)

Usage

Description

(4-Carboxy-3-ethoxy)phenyl Acetic Acid (Repaglinide Impurity) is a chemical compound that is identified as an impurity in the pharmaceutical drug Repaglinide. It is characterized by its white to off-white solid appearance and is a result of the synthesis process of the parent drug.

Uses

Used in Pharmaceutical Industry:
(4-Carboxy-3-ethoxy)phenyl Acetic Acid (Repaglinide Impurity) is used as a reference material for quality control and assurance in the manufacturing process of Repaglinide. Its presence is monitored and controlled to ensure the purity and safety of the final drug product.
Additionally, understanding the properties and effects of this impurity can contribute to the optimization of the synthesis process, potentially leading to improved efficiency and reduced impurity levels in the final product. This can be crucial for maintaining the therapeutic efficacy and safety profile of Repaglinide, which is used for the treatment of type 2 diabetes.

InChI:InChI=1S/C11H12O5/c1-2-16-9-5-7(6-10(12)13)3-4-8(9)11(14)15/h3-5H,2,6H2,1H3,(H,12,13)(H,14,15)

Upstream product

• 50-85-1 2-hydroxy-p-toluic acid 
• 88709-17-5 ethyl 2-ethoxy-4-methyl-benzoate 
• 110017-07-7 ethyl 4-bromomethyl-2-ethoxy-benzoate 
• 99470-01-6 ethyl 4-cyanomethyl-2-ethoxy-benzoate 
• 99469-99-5 2-(3-ethoxy-4-(ethoxycarbonyl)phenyl) acetic acid 
• 124-38-9 carbon dioxide 
• 1379370-52-1 4-chloromethyl-2-ethoxychlorobenzene 
• 503834-19-3 2-(3-ethoxy-4-(methoxycarbonyl)phenyl)acetic acid 

Downstream Products

• 332347-69-0 ethyl 2-ethoxy-4-ethoxycarbonylmethyl-benzoate 
• 1803084-80-1 C₂₇H₃₆N₂O₄ 

Relevant articles and documents

Two d10 metal–organic frameworks based on a novel semi-rigid aromatic biscarboxylate ligand: Syntheses, structures and luminescent properties

Two new d10 metal–organic frameworks based on a novel semi-rigid aromatic biscarboxylate ligand, namely, [Zn (RGAA)(BPY)1/2] (1) and [Cd5(μ3-OH)2(RGAA)4] (2) [H2RGAA = 4-(carboxymethyl)-2-ethoxybenzoic acid, BPY = 4,4′-bipyridine], have been synthesized by the hydrothermal reaction, and characterized by Fourier transform-infrared, elemental analyses, X-ray single-crystal diffraction, powder X-ray diffraction and thermogravimetric analyses. Complex 1 displays a three-dimensional (3D) network with a (2,3,4)-connected (6?3.8?2.10)2(6?3)2(8) topology, while complex 2 exhibits a 3D framework with a (3,10)-connected (3.4.5)2(3?4.4?6.5?18.6?14.7?2.8) topology. The luminescent properties of compounds 1 and 2 have been investigated in detail, where the emission maxima are 464 and 349 nm, respectively.

Preparation method of 3-ethoxy-4-carbozylbenzoic acid

The invention discloses a preparation method of 3-ethoxy-4-carbozylbenzoic acid. The preparation method includes: taking dihalide (IV) as a starting raw material, reacting with metal magnesium to prepare a di-Grignard reagent (V), allowing the di-Grignard

Process for the preparation of 3-ethoxy-4-(alkoxy carbonyl)-phenyl acetic acid. (an intermediate of repaglinide)

The present invention relates to an improved and convenient process for the preparation of 3-Ethoxy-4-(alkoxy carbonyl)-phenyl acetic acid, which can be represented by formula (Ia) where R1 represents ethyl or methyl. Specifically the present invention relates to an improved process for the preparation of compound of formula (Ia), which is the key intermediate for Repaglinide of formula (I), by the process, which involves non-hazardous raw materials with an easy handling, and cost effective process